Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 519-531

  Hoffman, Hal M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cryopyrin associated periodic syndromes; IL 1 trap; Interleukin 1; Rilonacept

Indexed keywords

AMYLOID A PROTEIN; ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; CELL PROTEIN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALICYLIC ACID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AMYLOIDOSIS; ARTHRALGIA; ATYPICAL MYCOBACTERIOSIS; AUTOINFLAMMATORY DISEASE; BIOAVAILABILITY; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONJUNCTIVITIS; COUGHING; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERSENSITIVITY REACTION; HYPESTHESIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DERMATITIS; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INJECTION SITE VESICLE; INJECTION SITE WARMTH; LIPID BLOOD LEVEL; MUCKLE WELLS SYNDROME; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PEDIATRICS; PILOT STUDY; PNEUMOCOCCAL MENINGITIS; RASH; REVIEW; RISK FACTOR; SINUSITIS; STOMACH DISCOMFORT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ANIMALS; CARRIER PROTEINS; CLINICAL TRIALS, PHASE III AS TOPIC; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; SYNDROME; TREATMENT OUTCOME;

EID: 67649286668     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902875518     Document Type: Review

References (47)

1. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003;15:61-69 (Pubitemid 36021025)
2. Aksentijevich I, Putnam DC, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-1285 (Pubitemid 46608652)
3. Hoffman HM. Familial cold autoinflammatory syndrome. Orphanet Encyclopedia 2005;1-4
4. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/ CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002;46:2445-2452
5. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001;108:615-620 (Pubitemid 32978035)
6. Goldbach-Mansky R, Dailey NJ, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355(6):581-592 (Pubitemid 44200651)
7. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-612 (Pubitemid 38198844)
8. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatalonset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-3348 (Pubitemid 35453546)
9. Kastner DL. Hereditary periodic fever syndromes. Hematology 2005 - American Society of Hematology Education Program. 2005;74-81
10. Boschan C, Witt O, Lohse P, et al. Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A 2006;140:883-886
11. Stefaniak R, Maurer M, Mahony M, et al. Burden of disease in patients with Muckle Wells Syndrome (MWS): baseline results from a natural history study. Abstract presented at American College of Rheumatology, 2008
12. Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008;24:1577-1582 (Pubitemid 351929056)
13. Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ. Cryopyrin-associated periodic syndromes: development of a patientreported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 2008;29:2531-2543
14. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203 (Pubitemid 34734724)
15. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature 2001;29:301-305 (Pubitemid 33096455)
16. Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29:803-808 (Pubitemid 351794131)
17. Hoffman HM, Gregory SG, Mueller JL, et al. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 2003;112(2):209-216 (Pubitemid 36869106)
18. Hoffman HM, Patel DD. Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum 2004;50:345-349 (Pubitemid 38198816)
19. Saito M, Nishikomori R, Kambe N, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 2008;111:2132-2141
20. Boutin H, Kimber I, Rothwell NJ, Pinteaux E. The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/ signaling pathways exist in the brain? Mol Neurobiol 2003;27:239-248
21. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147 (Pubitemid 26086851)
22. Dinarello CA. Unraveling the NALP-3/ IL-1β inflammasome: a big lesson from a small mutation. Immunity 2004;20:243-246 (Pubitemid 38388225)
23. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-325 (Pubitemid 38388233)
24. Janssen R, Verhard E, Lankester A, et al. Enhanced interleukin-1β and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004;50:3329-3333 (Pubitemid 39372011)
25. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1 receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;48:2583-2584 (Pubitemid 36706554)
26. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (IL-1 trap) in cryopyrin-associated periodic syndromes (CAPS): results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-2452
27. O'Connell SM, O'Regan GM, Bolger T, et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007;24:85-89 (Pubitemid 46245630)
28. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-1785 (Pubitemid 39488063)
29. Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008;12(1):8-16
30. Chang DM, Chang SY, Yeh MK, Lai JH. The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis. Pharmacol Res 2004;50:371-376 (Pubitemid 38844494)
31. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-624 (Pubitemid 34214243)
32. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-896
33. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007;56(10):3183-3188 (Pubitemid 47585412)
34. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-1359 (Pubitemid 40664079)
35. Dinarello CA. Setting the cytokine trap for autoimmunity. Nat Med 2003;1:20-22 (Pubitemid 36098253)
36. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52 (Pubitemid 36098259)
37. ARCALYST™ (rilonacept) full prescribing information. Regeneron Pharmaceuticals, Inc. 2008
38. Data on file, Regeneron Pharmaceuticals, Tarrytown, NY
39. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419 (Pubitemid 38608062)
40. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:2432-2442
41. Hoffman HM, Amar NJ, Cartwright RC, et al. Durability of response to rilonacept (IL-1 Trap) in a Phase 3 study of patients with cryopyrin-associated periodic syndromes (CAPS): familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) [abstract]. American Academy of Allergy, Asthma & Immunology 8th Annual Meeting, March 14-18, 2008, Philadelphia, PA
42. Braddock M, Quinn A, Canvin J. Therapeutic potential targeting IL-1 and IL-18 inflammation. Expert Opin Biol Ther 2004;4:847-860 (Pubitemid 38843222)
43. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204 (Pubitemid 29009378)
44. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-1009 (Pubitemid 30368176)
45. Rosengren S, Mueller JL, Anderson JP, et al. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J Allergy Clin Immunol 2007;119:991-996 (Pubitemid 46527817)
46. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299:2076-2079 (Pubitemid 36383736)
47. Wanderer A. An "allergy" to cold. Hosp Pract 1979;14:135-137